

Graefe's Archive for Clinical and Experimental Ophthalmology

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)

Taiji Sakamoto, Masahiko Shimura, Shigehiko Kitano, Masahito Ohji, Yuichiro Ogura, Hidetoshi Yamashita, Makoto Suzaki, Kimie Mori, Yohei Ohashi, Poh Sin Yap, Takeumi Kaneko, Tatsuro Ishibashi, for the MERCURY Study Group

Corresponding author:

Taiji Sakamoto

Department of Ophthalmology, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan

Tel: +81 99-275-5402

Fax: +81 99-265-4894

Email: tsakamot@m3.kufm.kagoshima-u.ac.jp

Online Resource 14. Visual acuity gain during anti-VEGF therapy for diabetic macular oedema: Real-world data

Study	Patients, <i>n</i>	Eyes, <i>n</i>	Follow-up, months	Treatment regimen	Anti-VEGF	Mean change in	
					injections at month 12, mean $\pm$ SD	BCVA (ETDRS) from baseline to month 12	BCVA (ETDRS) from baseline to month 12
MERCURY	209	209 ^a	12	ND	3.6 $\pm$ 2.4	63.5	4
Moorfields DME	164	200	12	3+PRN	7.2 $\pm$ 2.3	54.4	6.6
Patrao et al. 2016 [25]							
Epstein et al. 2018 [30]	80	102	48	3+PRN	7.7 $\pm$ 3.4 ^b	60.8	6.6 ^b
Holekamp et al. 2018 [26]	110	121	12	ND	3.1 $\pm$ 2.4	56.9	4.7
OCEAN	1,226	-	12	ND	4.4	60.6	4
Ziemssen et al.							

2018 [27]

STREAT-DME	1,552	2,049	24	ND	3.8 ± 3.3^c	63	2 ^c
------------	-------	-------	----	----	-----------------	----	----------------

Shimura et al.

2020 [31]

BOREAL-DME	290	290	12	ND	5.1 ± 2.3	59.2	7.4
------------	-----	-----	----	----	---------------	------	-----

Massin et al. 2019

[28]

LUMINOUS	1,049	-	12	ND	4.5 ± 2.5	57.7	3.5
----------	-------	---	----	----	---------------	------	-----

Mitchell et al.

2020 [29]

^aPrimary treated eyes. ^b4-year data. ^c2-year data.

BCVA, best-corrected visual acuity; ETDRS, early treatment diabetic retinopathy study; ND, not determined; PRN, *pro re nata*; SD, standard deviation; VEGF, vascular endothelial growth factor.